7-hydroxy-5,11-dioxotetranorprostane-1,16-dioic acid and Local Neoplasm Recurrence

7-hydroxy-5,11-dioxotetranorprostane-1,16-dioic acid has been researched along with Local Neoplasm Recurrence in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bernstein, E; Burrows, F; Gitlitz, BJ; Milne, G; Otterson, GA; Santos, ES; Syto, M; Zaknoen, S	1
Carbone, DP; Csiki, I; Dang, T; Johnson, DH; Morrow, JD; Oates, J; Sandler, A; Shyr, Y; Williams, MK	1

Trials

2 trial(s) available for 7-hydroxy-5,11-dioxotetranorprostane-1,16-dioic acid and Local Neoplasm Recurrence

Article	Year
A randomized, placebo-controlled, multicenter, biomarker-selected, phase 2 study of apricoxib in combination with erlotinib in patients with advanced non-small-cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2014, Volume: 9, Issue:4 Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cyclooxygenase 2 Inhibitors; Disease Progression; Double-Blind Method; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Prostaglandins; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Sulfonamides; Survival Rate	2014
Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a phase II trial of celecoxib and docetaxel. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Sep-15, Volume: 11, Issue:18 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inducing Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cohort Studies; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Docetaxel; Endostatins; Female; Hematologic Diseases; Humans; Lung Neoplasms; Male; Membrane Proteins; Middle Aged; Nausea; Neoplasm Recurrence, Local; Prostaglandin-Endoperoxide Synthases; Prostaglandins; Pyrazoles; Sulfonamides; Survival Analysis; Taxoids; Treatment Outcome; Vascular Endothelial Growth Factor A; Vomiting	2005

Article

Year

A randomized, placebo-controlled, multicenter, biomarker-selected, phase 2 study of apricoxib in combination with erlotinib in patients with advanced non-small-cell lung cancer.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2014, Volume: 9, Issue:4

Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cyclooxygenase 2 Inhibitors; Disease Progression; Double-Blind Method; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Prostaglandins; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Sulfonamides; Survival Rate

2014

Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a phase II trial of celecoxib and docetaxel.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Sep-15, Volume: 11, Issue:18

Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inducing Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cohort Studies; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Docetaxel; Endostatins; Female; Hematologic Diseases; Humans; Lung Neoplasms; Male; Membrane Proteins; Middle Aged; Nausea; Neoplasm Recurrence, Local; Prostaglandin-Endoperoxide Synthases; Prostaglandins; Pyrazoles; Sulfonamides; Survival Analysis; Taxoids; Treatment Outcome; Vascular Endothelial Growth Factor A; Vomiting

2005